Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02470702 · ClinicalTrials.gov registry record · Phase 1
Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects
A Phase 1 study, sponsored by Melinta Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT02470702 is a Phase 1 study that has completed, run by Melinta Therapeutics. The registered enrollment target is 14 participants.
The verdict
NCT02470702, a Phase 1 study, has completed, sponsored by Melinta Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This protocol describes a double-blind study to evaluate the safety and pharmacokinetics of multiple IV doses of 1200 mg ORBACTIV (oritavancin) in healthy subjects.
Interventions
- DRUG Oritavancin
- DRUG Placebo (D5W)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2015-06 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02470702
The ClinicalTrials.gov registry entry for NCT02470702 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Melinta Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oritavancin is the first listed.
NCT02470702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02470702 about?
NCT02470702 is a clinical study titled "Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects". This protocol describes a double-blind study to evaluate the safety and pharmacokinetics of multiple IV doses of 1200 mg ORBACTIV (oritavancin) in healthy subjects.
What is the current status of trial NCT02470702?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2015-06. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02470702?
The interventions under investigation include: Oritavancin (DRUG), Placebo (D5W) (DRUG).
Who is sponsoring clinical trial NCT02470702?
This trial is sponsored by Melinta Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.